The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)

by Huntgeburth, Michael, Kießling, Johannes, Weimann, Gerrit, Kiepsel, Verena, Saleh, Soundos, Hunzelmann, Nicolas, Rosenkranz, Stephan
Published 2015

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food

by Saleh, Soundos, Frey, Reiner, Becker, Corina, Unger, Sigrun, Wensing, Georg, Mück, Wolfgang
Published 2015

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

by Rosenkranz, Stephan, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Frey, Reiner, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian
Published 2015

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies

by Stephan, Rosenkranz, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian, Frey, Reiner
Published 2015